The medications ability to increase feelings of fullness and reduce hunger makes it particularly effective for those struggling to lose weight through only diet changes and exercise
As more individuals face health risks associated with excess weight, the demand for GLP-1 receptor agonist, proven to reduce weight, improve glycemic control and lower cardiometabolic risk, is expected to rise substantially, thereby driving the growth of the GLP-1 receptor agonist market
You can also refer directly to the manufacturer Novo Nordisks prescribing information One stat worth noting: according to foundational data, around 90% of weekly semaglutide users experience some form of adverse event or side effectbut only 7% of users have to stop taking semaglutide as a result
We recommend that you aim for an appointment one to two days before the date in question
Comparing options for actual, evidence-based weight loss If deliberate weight loss is your goal, there are options with stronger trial evidence than B12 injections alone
References Carson SA, Kallen AN
